Fulgent Genetics (FLGT)
(Real Time Quote from BATS)
$20.72 USD
-0.69 (-3.22%)
Updated Sep 25, 2024 01:34 PM ET
2-Buy of 5 2
C Value C Growth A Momentum B VGM
Cash flow Statements
Fiscal Year End for Fulgent Genetics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -175.24 | 141.92 | 506.24 | 214.31 | -0.41 |
Depreciation/Amortization & Depletion | 142.47 | 37.43 | 18.60 | 3.82 | 2.21 |
Net Change from Assets/Liabilities | 2.84 | 2.01 | -2.68 | -91.45 | -0.92 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 56.94 | 72.16 | 16.41 | 13.95 | 4.63 |
Net Cash From Operating Activities | 27.00 | 253.52 | 538.58 | 140.63 | 5.52 |
Property & Equipment | -21.43 | -18.36 | -23.75 | -36.50 | -1.32 |
Acquisition/ Disposition of Subsidiaries | -0.40 | -172.68 | -61.87 | 0.00 | 0.00 |
Investments | 60.73 | -45.27 | -440.90 | -289.94 | -27.73 |
Other Investing Activities | 0.00 | -25.00 | -20.03 | 0.00 | 0.00 |
Net Cash from Investing Activities | 38.90 | -261.31 | -546.55 | -326.44 | -29.05 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -27.79 | -76.07 | 85.41 | 246.23 | 28.78 |
Issuance (Repayment) of Debt | -5.00 | -1.07 | -0.01 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | -15.00 | 0.00 | 0.00 | 15.02 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 |
Net Cash from Financing Activities | -47.79 | -77.14 | 85.41 | 261.25 | 28.78 |
Effect of Exchange Rate Changes | -0.15 | -0.45 | 0.03 | 0.02 | -0.02 |
Net Change In Cash & Equivalents | 17.97 | -85.39 | 77.47 | 75.46 | 5.23 |
Cash at Beginning of Period | 79.51 | 164.89 | 87.43 | 11.97 | 6.74 |
Cash at End of Period | 97.47 | 79.51 | 164.89 | 87.43 | 11.97 |
Diluted Net EPS | -5.63 | 4.63 | 16.38 | 8.91 | -0.02 |
Fiscal Year End for Fulgent Genetics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -22.94 | -13.85 | -175.24 | -40.91 | -27.44 |
Depreciation/Amortization & Depletion | 10.15 | 5.48 | 142.47 | 17.23 | 12.00 |
Net Change from Assets/Liabilities | 2.33 | 4.91 | 2.84 | -7.39 | 3.79 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 22.02 | 10.73 | 56.94 | 43.14 | 13.49 |
Net Cash From Operating Activities | 11.55 | 7.27 | 27.00 | 12.07 | 1.83 |
Property & Equipment | -16.73 | -3.80 | -21.43 | -18.66 | -13.76 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | -0.40 | 0.00 | 0.00 |
Investments | -23.16 | -43.39 | 60.73 | 33.29 | 8.31 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -39.88 | -47.19 | 38.90 | 14.63 | -5.45 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -2.45 | -1.91 | -27.79 | -3.81 | -1.10 |
Issuance (Repayment) of Debt | -1.50 | -0.90 | -5.00 | -3.02 | -1.26 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | -15.00 | -15.00 | -15.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | -3.95 | -2.81 | -47.79 | -21.83 | -17.36 |
Effect of Exchange Rate Changes | -0.08 | -0.07 | -0.15 | -0.29 | -0.18 |
Net Change In Cash & Equivalents | -32.36 | -42.80 | 17.97 | 4.57 | -21.16 |
Cash at Beginning of Period | 97.47 | 97.47 | 79.51 | 79.51 | 79.51 |
Cash at End of Period | 65.11 | 54.68 | 97.47 | 84.08 | 58.35 |
Diluted Net EPS | -0.29 | -0.45 | -4.29 | -0.44 | -0.38 |